Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 4:07 AM
Ignite Modification Date:
2025-12-25 @ 4:07 AM
NCT ID:
NCT02929420
Eligibility Criteria:
Inclusion Criteria:
* 18-65 years old female patients with cyclomastopathy who signed a written informed consent.
* The subjects voluntarily entered the clinical observation whom are hospitalized patients or outpatients with good compliance.
* They have specific symptoms, such as distending pain of the breast, stabbing pain, dull pain and radiating pain.
* They have specific physical sign, for example, we can touch block gland, granular, nodular or cord like glands and etc..
* Breast ultrasound or molybdenum target show I-III class by Breast Imaging Reporting and Data System.
Exclusion Criteria:
* Women who are pregnant or lactating, and who has the history of periarthritis of shoulder.
* Excluding breast fibrocellular tumor, breast cancer and other breast diseases.
* Patients with poor self coordination, mentally retarded patients, or have cardiovascular and cerebrovascular disease, severe organic disease, as well as the hematopoietic system disease or mental illness.
* Be judged as over middle degree depression by the Hamilton's depression scale.
* Allergic constitution patients, and people who are allergic to a variety of drugs.
* Any medical history which may interfere with the test results or increase the risk of patients according to the investigators.
* Patients who have received treatment of other diseases, and those treatment methods and targets may have an impact on the indicators of this study.
Healthy Volunteers:
False
Sex:
FEMALE
Minimum Age:
18 Years
Maximum Age:
65 Years
Study:
NCT02929420
Study Brief:
Protocol Section:
NCT02929420